WVE News and Press, Wave Life Sciences Ltd. From 12/07/23

2023-12-07 07:16:38 ET More on Wave Life Sciences Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash Wave Life Sciences proposes public offering of ordinary shares and pre-funded w...

2023-12-06 16:18:00 ET More on Wave Life Sciences Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash Wave Life Sciences GAAP EPS of $0.07 beats by $0.25, revenue of $49.2M beats by...

CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $10...

WVE-006 is uniquely designed to correct the disease-causing RNA mutation in AATD, thereby restoring circulation of wild-type M-AAT protein and reducing Z-AAT protein levels to address both lung and liver manifestations of the disease Wave earned $20 million USD milestone from GSK for in...

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...

CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Offi...

2023-11-10 12:04:06 ET Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Conference Call November 09, 2023 08:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer ...

2023-11-09 07:33:57 ET More on Wave Life Sciences Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash Wave Life Sciences Q3 2023 Earnings Preview Wave Life Sciences spikes on R&D Day Seeking Alpha’s Quant Rating on Wave Life ...

Initiated RestorAATion clinical program for WVE-006, industry’s first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism data anticipated in 2024 On track to deliver dystrophin data from p...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...